For more than two decades, the debate of menopause hormone therapy evolved around a simple yes-or-no question: safe or dangerous? That oversimplified view has let women down.
In November, the U.S. Food and Drug Administration removed the black-box label from low-dose vaginal estrogen and softened language on systemic therapy. It happened quietly, but signals something important—hormone therapy was never meant to be one-size-fits-all.
We had a problem loading this article. Please enable javascript or use a different browser. If the issue persists, please visit our help center.
